Needham raised the firm’s price target on Trevi Therapeutics (TRVI) to $25 from $8 and keeps a Buy rating on the shares. The firm cites the company’s positive results from its RIVER trial evaluating Haduvio in refractory chronic cough, or RCC, noting that the trial met its primary endpoint with efficacy levels that exceed other RCC programs in development across key endpoints, the analyst tells investors in a research note. Importantly, Haduvio’s efficacy was consistent across moderate and severe RCC, the firm added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TRVI:
- Trevi Therapeutics upgraded to Strong Buy from Outperform at Raymond James
- Trevi Therapeutics RIVER trial meets primary endpoint
- Trevi Therapeutics completes enrollment for Phase 2b trial of Haduvio in cough
- Trevi Therapeutics price target raised to $12 from $9 at Oppenheimer
- Trevi Therapeutics price target raised to $12 from $8 at Stifel